Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT study

José-Artur Paiva 1*, José Manuel Pereira 1, Alexis Tabah 2,3,4, Adam Mikstacki 5, Frederico Bruzzi de Carvalho 6, Despoina Koulenti 3,7, Stéphane Ruckly 4,8, Nahit Çakar 9, Benoit Misset 10, George Dimopoulos 7, Massimo Antonelli 11, Jordi Rello 12, Xiaochun Ma 13, Barbara Tamowicz 5 and Jean-François Timsit 2,4,8,14

Abstract

Background: To characterize and identify prognostic factors for 28-day mortality among patients with hospital-acquired fungemia (HAF) in the Intensive Care Unit (ICU).

Methods: A sub-analysis of a prospective, multicenter non-representative cohort study conducted in 162 ICUs in 24 countries.

Results: Of the 1156 patients with hospital-acquired bloodstream infections (HA-BSI) included in the EUROBACT study, 96 patients had a HAF. Median time to its diagnosis was 20 days (IQR 10.5–30.5) and 9 days (IQR 3–15.5) after hospital and ICU admission, respectively. Median time to positivity of blood culture was longer in fungemia than in bacteremia (48.7 h vs. 38.1 h; p = 0.0004). Candida albicans was the most frequent fungus isolated (57.1 %), followed by Candida glabrata (15.3 %) and Candida parapsilosis (10.2 %). No clear source of HAF was detected in 33.3 % of the episodes and it was catheter-related in 21.9 % of them. Compared to patients with bacteremia, HAF patients had a higher rate of septic shock (39.6 % vs. 21.6 %; p = 0.0003) and renal dysfunction (25 % vs. 12.4 %; p = 0.0023) on admission and a higher rate of renal failure (26 % vs. 16.2 %; p = 0.0273) at diagnosis. Adequate treatment started within 24 h after blood culture collection was less frequent in HAF patients (22.9 % vs. 55.3 %; p < 0.001). The 28-day all cause fatality was 40.6 %. According to multivariate analysis, only liver failure (OR 14.35; 95 % CI 1.17–175.6; p = 0.037), need for mechanical ventilation (OR 8.86; 95 % CI 1.2–65.24; p = 0.032) and ICU admission for medical reason (OR 3.87; 95 % CI 1.25–11.99; p = 0.020) were independent predictors of 28-day mortality in HAF patients.

Conclusions: Fungi are an important cause of hospital-acquired BSI in the ICU. Patients with HAF present more frequently with septic shock and renal dysfunction on ICU admission and have a higher rate of renal failure at diagnosis. HAF are associated with a significant 28-day mortality rate (40 %), but delayed adequate antifungal therapy was not an independent risk factor for death. Liver failure, need for mechanical ventilation and ICU admission for medical reason were the only independent predictors of 28-day mortality.

Background

Bloodstream infection(s) (BSI) in the critically ill patients are a major cause of morbidity and mortality. The prevalence varies between centers, representing 15 % of all nosocomial infections in a recent, large, multicenter prevalence study [1]. The prognosis of BSI also varies, depending on several factors related to the host, the pathogen and the antimicrobial agent.

Fungi are responsible for around 20 % of all microbiologically documented infections in the Intensive Care Unit (ICU) [1]. The incidence of invasive fungal infections has increased steadily, namely due to the increasing number of both immunocompromised and critically ill patients. In the last decades, we faced a worldwide rise in the prevalence of candidemia, particularly in the ICU [2–6]. Data from surveillance programs from the...
USA and Europe showed that Candida spp. is responsible for 2–11% of hospital-acquired BSI (HA-BSI) and it represents 8.3% of patients with HA-BSI hospitalized in ICUs [7]. It is the fourth cause of nosocomial BSI in the USA and the fifth to the tenth most common pathogen in Europe [8–11].

Candidemia is a severe disease linked to significant morbidity and mortality [3, 12, 13] ranging from 35–75% [14, 15]. Outstandingly, after controlling for confounders, candidemia has been identified as an independent predictor of mortality [16]. In addition, it prolongs hospital length of stay and increases costs associated with patient management [13, 17]. Therefore, it is important to identify potentially modifiable prognostic factors to improve this poor outcome. Few independent prognostic factors have been identified in critically ill patients with candidemia. Adequate initial therapy is of paramount importance for a successful outcome. In general, early administration of antimicrobial agents is associated with a better outcome [18]. However, contradictory results have been published on the timing of antifungal therapy [19].

The goal of this sub-analysis of the Epidemiology and outcome of hospital-acquired bacteremia (EUROBACT) study was to characterize the population of patients with hospital-acquired fungemia (HAF) admitted to ICUs worldwide and to identify prognostic factors for 28-day mortality, including timing of antifungal therapy, in these patients.

Methods
A prospective observational multicenter international cohort design was used. The international database was declared to the CNIL (Commission Nationale de l’Informatique et des Libertés). The French ethics committee waived the need for informed consent for French centers. Similar authorization was obtained from countries such as Portugal (Centro Hospitalar S. João), Poland (Poznan University of Medical Sciences) and Australia (Royal Brisbane and Women’s Hospital) and it was waived in the other countries due to the observational nature of the study.

Study protocol and definitions
Patients were enrolled if they had a new diagnosis of HA-BSI and were admitted to an ICU. The study focused on the first episode of HA-BSI, either being ICU-acquired or acquired before admission to ICU. The detailed protocol has been described previously [7]. Data collected for each patient included the dates and times of collection and of positivity of the first positive blood culture; source of infection; presence of sepsis; severity of illness; comorbidities; and infection management, including source control, antimicrobial drugs and adjunctive treatments. Organ dysfunction and organ failure were defined as Sequential Organ Failure Assessment (SOFA) scores ≥0 and ≥3, respectively. All study data were obtained from patient files, and no additional tests were performed for the purpose of the study. Severity of illness was defined at ICU admission using the Simplified Acute Physiology Score (SAPS) II [20] and at HA-BSI diagnosis using the SOFA score [21]. Comorbidities were assessed using the Charlson index and the five markers of the Chronic Health Evaluation from the Acute Physiology and Chronic Health Evaluation (APACHE) II score, as reported by Knaus et al. [22]. Clinical variables and relapses or new episodes of HA-BSI were recorded until ICU discharge, and the all-cause mortality within 28 days of the first positive blood culture were ascertained.

Data management and statistical analysis
A control quality check has been detailed previously [7]. The statistical analysis was based only on the first episode of HA-BSI, as this was the only episode for which full information was available. The medians and interquartile range (IQR) was computed for continuous data and Fisher’s exact test or the chi-square test was performed to compare categorical data. We compared characteristics of patients with bacteremia and patients with fungemia, using univariate hierarchical logistic regression models, including random effects for country and center. Time to death was plotted using Kaplan–Meier curves and compared using a frailty Cox model, treating the center as a random effect. For patients with fungemia, risk factors for death were analyzed using hierarchical models. The variables were organized into three tiers: country, ICU and patient. To identify factors associated with day-28 mortality, we built a three-tiered hierarchical logistic mixed model using the GLIMMIX procedure in the SAS software. The influence of country-based and ICU-based variables on the outcome was included through both fixed and random effects. Multilevel modeling takes into account the hierarchical structure of the data, which may manifest as intra-class correlations. To obtain a conservative estimate of the standard error, a separate random-error term should be specified for each level of the analysis. Therefore, to avoid overestimating the significance of risk factors for death by day 28, we took intra-class correlation into account, and we specified a separate random-error term for each tier. Variables potentially associated with day-28 mortality (p values <0.20 by univariate analysis) were introduced into the multivariable model and selected using a backward approach. Two-way clinically relevant interactions were tested in the final model. In all analysis, two-sided p values <0.05 were deemed statistically significant. No correction for multiple testing was performed.
Results
A fungus was recovered from the blood in 96 of the 1,156 patients (8.3 %) with HA-BSI admitted to an ICU, included in the EUROBACT study [7]. Patients with HAF were mostly male (67.7 %) with a median age of 61 years (IQR 48–73) and a median SAPS II score of 49 (IQR 41–63) (Table 1). They were mostly admitted to the ICU for medical reasons (63.5 %), 60 % of these with acute respiratory failure requiring ventilator support and 24 % with a cardiac-related syndrome: 35 % of the patients had a Charlson co-morbidity index ≥3. A chronic illness was present in 41.7 % of patients, mainly immunosuppressive (15.6 %), cardiovascular (14.6 %) and respiratory (12.5 %) chronic illnesses.

At ICU admission, at least one organ failure was documented in a significant number of patients (89.6 %). Respiratory (82.3 %) and cardiovascular (63.5 %) were the most prevalent organ dysfunctions followed by neurological (29.2 %) and renal (25 %). Septic shock was diagnosed in 39.6 % of the patients and it was present at diagnosis of HAF in half of the episodes.

The median time to diagnosis of HAF was 20 days (IQR 10.5–30.5) after hospital admission and 9 days (IQR 3–15.5) after ICU admission (Table 2). In fact, more than half of the episodes (56.3 %) occurred after the first week in the ICU. However, a significant number of patients (22.9 %) had already presented with HAF on ICU admission.

Median time to blood culture positivity in fungemia was 48.7 hours (IQR 33–81). There was no clear source of fungemia in 32 patients (33.3 %) and in 21 patients (21.9 %) it was catheter-related, based upon culture results yielding identical microorganisms. The abdomen was the source of infection in 12 patients (12.5 %) (Table 2). Source control was required in 43.8 % of patients and was performed in 39.6 % of the patients (Table 2).

The characteristics on admission of patients with fungemia and of those with bacteremia were similar except for a higher rate of septic shock and renal dysfunction in fungemic patients (Table 1). At diagnosis, patients with HAF presented with a significantly higher rate of renal failure than bacteremic patients. Delay from hospital admission to HA-BSI diagnosis was not significantly different between bacteremic and fungemic patients (13 days (7–25) vs 20 days (10.5–30.5), \( p = 0.13 \)). Delay of positivity of culture sampling was significantly longer for fungemia (38.1 hours (21.1–69.2) vs 48.7 (33–81), \( p = 0.0004 \)) (Table 2 and Fig. 1). There was no significant difference between these two groups of patients in time to death (Fig. 2).

On comparing baseline characteristics in patients with ICU-acquired fungemia (n = 74) and HAF (n = 22), the

| Table 1 Baseline characteristics of patients with fungemia and patients with bacteremia |
| Variable | Bacteremia patients (n = 1,060) | Fungemia patients (n = 96) | \( P \) value |
|---|---|---|---|
| Age, median (IQR) | 62 (49–74) | 61 (48–73.5) | 0.7077 |
| Male gender, n (%) | 691 (65.2) | 65 (67.7) | 0.6155 |
| Simplified Acute Physiology Score II, median (IQR) | 48 (38–59) | 49 (41–63) | 0.0993 |
| Medical admission, n (%) | 611 (57.6) | 61 (63.5) | 0.1799 |
| Charlson comorbidity index score, n (%) | 361 (34.1) | 25 (26) | 0.3215 |
| 0 | 361 (34.1) | 37 (38.5) | 0.0629 |
| 1–2 | 367 (34.6) | 34 (35.4) | 0.1286 |
| ≥3 | 332 (31.3) | 8 (8.3) | 0.1396 |
| Charlson comorbidity index score, n (%) | 361 (34.1) | 25 (26) | 0.3215 |
| 0 | 361 (34.1) | 37 (38.5) | 0.0629 |
| 1–2 | 367 (34.6) | 34 (35.4) | 0.1286 |
| ≥3 | 332 (31.3) | 8 (8.3) | 0.1396 |
| At least one chronic illness, n (%) | 336 (31.7) | 40 (41.7) | 0.0029 |
| Immunosuppression, n (%) | 136 (12.8) | 15 (15.6) | 0.5012 |
| Cardiovascular, n (%) | 103 (9.7) | 14 (14.6) | 0.202 |
| Respiratory, n (%) | 86 (8.1) | 12 (12.5) | 0.1286 |
| Renal, n (%) | 53 (5) | 8 (8.3) | 0.1396 |
| Liver, n (%) | 40 (3.8) | 4 (4.2) | 0.9752 |
| At least one organ dysfunction on admission, n (%) | 944 (89.1) | 86 (89.6) | 0.8491 |
| Cardiovascular, n (%) | 530 (50) | 61 (63.5) | 0.0222 |
| Respiratory, n (%) | 858 (80.9) | 79 (82.3) | 0.7319 |
| Neurologic, n (%) | 326 (30.8) | 28 (29.2) | 0.8062 |
| Renal, n (%) | 131 (12.4) | 24 (25) | 0.0023 |
| Septic shock at admission, n (%) | 229 (21.6) | 38 (39.6) | 0.0003 |
| Mortality at 28 days, n (%) | 375 (35.4) | 39 (40.6) | 0.2307 |
only difference was more frequent presence of at least one chronic illness ($p < 0.01$), namely immunosupression ($p < 0.01$) and cardiovascular disease ($p = 0.05$) in patients with HAF (Additional file 1: Table S1). The only significant difference in the characteristics of fungemia episodes at diagnosis, was a higher coagulation SOFA score in patients with HAF ($p < 0.01$) (Additional file 1: Table S2).

*Candida albicans* was the most frequent fungus isolated (57.1 %) followed by *Candida glabrata* (15.3 %) and *Candida parapsilosis* (10.2 %) (Table 3). Non-albicans *Candida* accounted for 39.6 % of HAF in this study.
More than one fungus was recovered from the blood of two of the patients. A mixed (bacterial and fungal) infection was documented in 15.6 % of the patients with fungemia.

In this study, 93.8 % of the patients received adequate treatment: 22.9 % of the patients received adequate treatment in the first 24 hours after blood culture collection, which was a significantly lower percentage than for bacteremia (55.3 %, \( p < 0.001 \)).

The 28-day all-cause mortality was 40.6 % (n = 39), slightly higher than in bacteremia (35.4 %). Non-survivors were older (64 years, IQR 50–76 vs 57 years IQR 46–71, \( p = 0.318 \)) and had higher SAPS II score (52 IQR 43–63 vs 47 IQR 37–63, \( p = 0.095 \)) but the differences were not statistically significant (Table 4). Fungemic patients admitted for a medical reason had significantly higher 28-day mortality (76.9 % vs 54.4 %, \( p = 0.038 \)). Neither the Charlson comorbidity index nor the presence of a chronic illness had a significant impact on the outcome. No association was found between sepsis syndrome severity at HAF diagnosis and mortality. In univariate analysis, the SOFA score at HA-BSI diagnosis was associated with a worse outcome. A SOFA score \( \geq 8 \) was more frequent in non-survivors (77 % vs 43.8 %, \( p = 0.004 \)). Furthermore, non-survivors had significantly higher SOFA scores for cardiovascular organ (\( p = 0.015 \)) and respiratory organ (\( p = 0.0019 \)) dysfunction. The presumed source of infection and the pathogen did not affect 28-day mortality. Delay of adequate treatment also did not affect outcome (Table 4). The proportion of patients who received adequate antifungal therapy in the first 24 hours after positive blood culture collection was higher (though not statistically significant) in non-survivors (28.2 % vs. 19.3 %; \( p = 0.694 \)).
On multivariable analysis (Table 5), the only variables independently associated with 28-day mortality were: liver SOFA score ≥3 (odds ratio (OR) 14.35, 95 % CI 1.17–175.6, p = 0.037), need for mechanical ventilation (OR 8.86, 95 % CI 1.2–65.24, p = 0.032) and ICU admission for medical reasons (OR 3.87, 95 % CI 1.25–11.99, p = 0.020). On multivariate analysis SOFA score was the only risk factor for death at 28 days in the subpopulation of patients with ICU-acquired fungemia (p = 0.0085).

### Discussion

This prospective, multicenter, observational study discloses that fungemia accounted for 8.3 % of the hospital-acquired BSI in patients admitted to the ICU. The mortality rate in HAF was high (40 %), but delayed adequate antifungal therapy was not an independent risk factor for death. The presence of septic shock and renal dysfunction on ICU admission and renal failure at BSI diagnosis were the only factors associated with fungemia in patients with BSI. In patients with HAF, multivariate logistic regression analysis identified liver SOFA score ≥3, need for mechanical ventilation and ICU admission for medical reasons as independent predictors of 28-day mortality.

Candidemia in critically ill patients is considered to be a severe and life-threatening condition. Recent data show that ICU and hospital mortality rates are usually between 36 % and 61 % [5, 6, 14, 15, 18, 23–26]. In our study, we observed 28-day mortality of 40.6 % which is in agreement with former findings [27] and is lower than the rates observed in recent Australian [19], Brazilian [26] and Spanish-Italian [18] studies.

Characteristics of bacteremic and fungemic patients at diagnosis are remarkably similar, namely in terms of the comorbidity index, immunosuppression and chronic organ illnesses, and only the presence of septic shock and renal dysfunction on ICU admission and renal failure at diagnosis were more frequent in patients with HA-BSI and fungemia than in those with bacteremia. Although delay in appropriate treatment was significantly longer for HAF, the outcome was similar in patients with fungemia and those with bacteremia.

Kumar et al. [28] observed strong correlation between shorter time to onset of antimicrobial treatment and reduced mortality in patients with septic shock. They showed that over the first 6 hours after the onset of persistent or recurrent hypotension, each hour of delay in initiating effective antimicrobial therapy was associated with a mean reduction in survival of 7.6 %, including the subgroup of patients with fungal infection. Nevertheless, the results of studies addressing the potential benefit of early antifungal therapy in patients with candidemia are conflicting.

In a small prospective multicenter study (n = 46 patients) [14], there was a higher (though not significant, p = 0.06) probability of survival among patients receiving early antifungal therapy (within ≤48 hours) compared with those treated 48 hours or more after the diagnosis of candidemia. A few years later, an independent association between delayed antifungal therapy (>48 hours) and in-hospital mortality (hazard ratio (HR) 2.1, 95 % CI 1.0–4.4, p = 0.05) was reported by Blot et al. [27]. According to Morrell et al. [29], mortality doubles when antifungal agents are administered ≥12 hours after the collection of the first positive blood culture and in another retrospective analysis of 230 patients with candidemia [30], initiation of fluconazole ≤24 hours after the first positive blood culture was associated with a significantly lower mortality rate. This positive effect of early antifungal therapy on survival was further confirmed in a group of patients with candidemia-associated septic shock who received treatment within 15 hours of blood culture collection [31]. Finally, in 216 patients hospitalized in five teaching hospitals in Italy and Spain (18), who had septic shock attributable to candidemia, adequate antifungal therapy, meaning both infecting organism susceptibility and adequate antifungal dosage within the first 24 hours of culture positivity, was one of the factors associated with 30-day survival.

However, some recent studies did not observe this beneficial association between timing of antifungal therapy and mortality in patients with candidemia [32–34]. Kludze-Forson et al. [35] observed a higher in-hospital mortality rate in patients receiving antifungal therapy within the first 24 hours (50 %) compared to 24–48 hours (28 %) and more than 48 hours (32 %) after blood culture collection. More recently, in a large retrospective study that included 446 patients with candidemia [36], there was neither a significant association between time from positive culture to administration of appropriate antifungal therapy and 30-day mortality, nor between timing of appropriate antifungal therapy and microbiological resolution of Candida bloodstream infection.

| Pathogen            | All fungemia | ICU acquired fungemia patients | Hospital acquired fungemia patients |
|---------------------|--------------|-------------------------------|-----------------------------------|
|                      | n = 98 (100 %) | n = 75 (76.5 %) | n = 23 (23.5 %) |
| _Candida albicans_, n (%) | 56 (57.1) | 44 (58.7) | 12 (52.7) |
| _Candida glabrata_, n (%) | 15 (15.3) | 12 (16.0) | 3 (13.0) |
| _Candida parapsilosis_, n (%) | 10 (10.2) | 7 (9.3) | 3 (13.0) |
| Other Candida, n (%) | 7 (7.1) | 5 (6.7) | 2 (8.7) |
| _Candida tropicalis_, n (%) | 6 (6.1) | 4 (5.3) | 2 (8.7) |
| Other fungi, n (%) | 3 (3.1) | 2 (2.7) | 1 (4.4) |
| _Candida krusei_, n (%) | 1 (1.0) | 1 (1.3) | 0 |
| Variable                                      | Dead (n = 39 patients) | Alive (n = 57 patients) | P value |
|-----------------------------------------------|------------------------|--------------------------|---------|
| Age, median (IQR)                             | 64 (50–76)             | 57 (46–71)               | 0.318   |
| SAPS II, median (IQR)                         | 52 (43–63)             | 47 (37–63)               | 0.095   |
| Male, n (%)                                   | 28 (71.8)              | 37 (64.9)                | 0.448   |
| Medical admission, n (%)                      | 30 (76.9)              | 31 (54.4)                | 0.038   |
| Charlson comorbidity index score, n (%)       |                        |                          | 0.5816  |
| 0                                             | 8 (20.5)               | 17 (29.8)                |         |
| 1–2                                           | 17 (43.6)              | 20 (35.1)                |         |
| ≥3                                            | 14 (35.9)              | 20 (35.1)                |         |
| At least one chronic illness, n (%)           | 16 (41)                | 24 (42.1)                | 0.982   |
| Immunosuppression, n (%)                      | 8 (20.5)               | 7 (12.3)                 | 0.271   |
| Cardiovascular, n (%)                         | 3 (7.7)                | 11 (19.3)                | 0.1245  |
| Respiratory, n (%)                            | 5 (12.8)               | 7 (12.3)                 | 0.811   |
| Renal, n (%)                                  | 2 (5.1)                | 6 (10.5)                 | 0.431   |
| Liver, n (%)                                  | 3 (7.7)                | 1 (1.8)                  | 0.174   |
| At least one organ dysfunction on admission, n (%) | 37 (94.9)             | 49 (86)                  | 0.187   |
| Cardiovascular, n (%)                         | 25 (64.1)              | 36 (63.2)                | 0.901   |
| Respiratory, n (%)                            | 34 (87.2)              | 45 (78.9)                | 0.284   |
| Neurologic, n (%)                             | 13 (33.3)              | 15 (26.3)                | 0.375   |
| Renal, n (%)                                  | 9 (23.1)               | 15 (26.3)                | 0.752   |
| Delay between ICU admission and fungemia, days, median (IQR) | 8 (4–13)               | 10 (3–21)                | 0.229   |
| Delay between hospital admission and fungemia, days, median (IQR) | 20 (10–29)             | 21 (11–32)               | 0.591   |
| Sepsis syndrome, n (%)                        |                        |                          | 0.301   |
| Sepsis                                        | 3 (7.7)                | 11 (19.3)                |         |
| Severe sepsis                                 | 14 (35.9)              | 20 (35.1)                |         |
| Septic shock                                  | 22 (56.4)              | 26 (45.6)                |         |
| SOFA, n (%)                                   |                        |                          | 0.004   |
| 0–4                                           | 3 (7.7)                | 14 (24.6)                |         |
| 5–7                                           | 6 (15.4)               | 18 (31.6)                |         |
| 8–11                                          | 12 (30.8)              | 19 (33.3)                |         |
| ≥12                                           | 18 (46.2)              | 6 (10.5)                 |         |
| SOFA score, respiratory, n (%)                |                        |                          | 0.019   |
| 0                                             | 4 (10.3)               | 8 (14)                   |         |
| 1                                             | 1 (2.6)                | 7 (12.3)                 |         |
| 2                                             | 8 (20.5)               | 23 (40.4)                |         |
| 3                                             | 13 (33.3)              | 16 (28.1)                |         |
| 4                                             | 13 (33.3)              | 3 (5.3)                  |         |
| SOFA score, cardiovascular, n (%)             |                        |                          | 0.015   |
| 0                                             | 9 (23.1)               | 19 (33.3)                |         |
| 1                                             | 4 (10.3)               | 12 (21.1)                |         |
| 2                                             | 1 (2.6)                | 4 (7)                    |         |
| 3                                             | 4 (10.3)               | 13 (22.8)                |         |
| 4                                             | 21 (53.8)              | 9 (15.8)                 |         |
Table 4 Risk factors for death at 28 days in the subpopulation with candidemia (univariate analysis) (Continued)

| SOFA score, neurological, n (%) | 0.249 |
|--------------------------------|-------|
| 0                              | 13 (33.3) | 17 (29.8) |
| 1                              | 5 (12.8)  | 14 (24.6)  |
| 2                              | 7 (17.9)  | 8 (14)     |
| 3                              | 4 (10.3)  | 11 (19.3)  |
| 4                              | 10 (25.6) | 7 (12.3)   |

| SOFA score, renal, n (%) | 0.122 |
|--------------------------|-------|
| 0                        | 11 (28.2) | 32 (56.1) |
| 1                        | 8 (20.5)  | 10 (17.5)  |
| 2                        | 5 (12.8)  | 5 (8.8)    |
| 3                        | 5 (12.8)  | 3 (5.3)    |
| 4                        | 10 (25.6) | 7 (12.3)   |

| SOFA score, coagulation, n (%) | 0.125 |
|-------------------------------|-------|
| 0                             | 19 (48.7) | 42 (73.7) |
| 1                             | 6 (15.4)  | 3 (5.3)    |
| 2                             | 4 (10.3)  | 7 (12.3)   |
| 3                             | 6 (15.4)  | 4 (7)      |
| 4                             | 4 (10.3)  | 1 (1.8)    |

| SOFA score, liver, n (%) | 0.142 |
|--------------------------|-------|
| 0                        | 26 (66.7) | 46 (80.7) |
| 1                        | 6 (15.4)  | 6 (10.5)   |
| 2                        | 1 (2.6)   | 4 (7)      |
| 3                        | 6 (15.4)  | 1 (1.8)    |

| Need for mechanical ventilation, n (%) | 0.094 |
|----------------------------------------|-------|
| No clear source                        | 12 (30.8) | 20 (35.1) |
| Catheter-related                       | 6 (15.4)  | 15 (26.3)  |
| Intra-abdominal                        | 8 (20.5)  | 4 (7)      |
| Respiratory                            | 6 (15.4)  | 8 (14)     |
| Urinary                                | 2 (5.1)   | 2 (3.5)    |
| Others                                 | 2 (5.1)   | 4 (7)      |
| Multiple sources, n (%)                | 3 (7.7)   | 4 (7)      |

| Delay of adequate treatment, n (%) | 0.694 |
|-----------------------------------|-------|
| <24 h                              | 11 (28.2) | 11 (19.3) |
| >24 h and ≤48 h                    | 9 (23.1)  | 14 (24.6)  |
| >48 h and ≤120 h                   | 12 (30.8) | 24 (42.1)  |
| >120 h or never                    | 7 (17.9)  | 8 (14)     |

| Antifungal treatment on the day of blood culture sampling, n (%) | 0.491 |
|----------------------------------------------------------------|-------|
| No clear source                                                  | 12 (30.8) | 20 (35.1) |
| Catheter-related                                                  | 6 (15.4)  | 15 (26.3)  |
| Intra-abdominal                                                   | 8 (20.5)  | 4 (7)      |
| Respiratory                                                       | 6 (15.4)  | 8 (14)     |
| Urinary                                                           | 2 (5.1)   | 2 (3.5)    |
| Others                                                            | 2 (5.1)   | 4 (7)      |
| Multiple sources                                                  | 3 (7.7)   | 4 (7)      |

| Candida pathogen, n (%) | 0.693 |
|-------------------------|-------|
| Candida albicans        | 23 (59) | 33 (57.9) |
| Candida parapsilosis    | 5 (12.8) | 5 (8.8)   |
| Others                  | 11 (28.2) | 19 (33.3) |

SOFA Sequential Organ Failure Assessment
Table 5 Risk factors for death at 28 days for candidemia subpopulation (multivariate analysis)

| Variable                        | Estimate (standard error) | Odds ratio (95 % CI) | P value |
|---------------------------------|---------------------------|----------------------|---------|
| Delay of adequate treatment     |                           |                      |         |
| ≤24 h, n (%)                    | Reference                 | 1                    | 0.8069  |
| >24 h and ≤48 h, n (%)          | −0.24 (0.74)              | 0.79 (0.18; 3.41)    | 0.7466  |
| >48 h and ≤120 h, n (%)         | −0.61 (0.66)              | 0.54 (0.15; 2.0)     | 0.3570  |
| >120 h or never, n (%)          | −0.15 (0.90)              | 0.86 (0.13; 5.14)    | 0.8717  |
| Medical admission               | 1.35 (0.57)               | 3.87 (1.25; 11.99)   | 0.0197  |
| SOFA score, liver (23)          | 2.66 (1.26)               | 14.35 (1.17; 175.6)  | 0.0373  |
| Need for mechanical ventilation | 2.18 (1.00)               | 8.86 (1.2; 65.24)    | 0.0325  |

Variables entered into the selection were the Simplified Acute Physiology Score II at ICU admission (per point); medical admission; septic shock at admission; type of ICU (open/closed); Sequential Organ Failure Assessment (SOFA) score; coagulation (>3); SOFA score, liver (>3); SOFA score, neurological (>3); SOFA score, renal (>3); mechanical ventilation and delay of adequate treatment.

Studies addressing only ICU-acquired candidemia, also failed to show this positive impact [19, 25, 37]. In the study of Marriott et al. [19], mean time to initiation of antifungal therapy was similar for non-survivors and survivors (2.0 ± 1.3 days vs 2.3 ± 1.6 days, p = 0.13), and Charles et al. [37] also observed that early therapy (≤48 hours after onset of candidemia) did not improve the outcome of patients with candidemia. Finally, a prospective, Spanish multicenter study showed that inadequate antifungal therapy was a factor independently associated with early mortality (0–7 days) in candidemia, but it had no impact on late mortality (8–30 days) [38].

In our study, four factors may contribute to the absence of impact of delayed adequate antifungal therapy on mortality. First, in critically ill patients, antifungal therapy is more likely to be started earlier than in non-ICU patients and, in fact, 22.9 % of the patients received adequate treatment within the first 24 hours and almost half of them within the first 48 hours after blood culture collection. Second, among critically ill patients any relationship between mortality and initiation of antifungal therapy may be hidden by the power of the patient’s acute illness as a determinant of outcome. Third, only half of our fungemia patients had septic shock at BSI diagnosis and the impact of early therapy is understandably higher in this subgroup of patients. Finally, timing to source control is a possible confounder that could not be analyzed, namely we did not collect data on the presence of a catheter, except on removal if it was deemed the source of the bloodstream infection.

Few prognostic factors have been identified in ICU patients with candidemia. In this cohort, the only independent prognostic factors associated with 28-day mortality were liver SOFA score ≥3, need for mechanical ventilation and ICU admission for medical reasons. Acute severity of illness is one important prognostic factor in candidemia. Among candidemic patients, the severity of organ dysfunction at fungemia onset evaluated by the SOFA score is a risk factor for mortality [39]. In our study, only liver failure was independently associated with 28-day mortality. In Candida bloodstream infection, this association between liver disease and outcome was previously reported but only for patients with chronic liver illness, which has a significant HR as an independent risk factor for 30-day mortality (HR 2.15, 95 % CI 1.48–3.13, p <0.001) [34]. There is also a relationship between other scores, such as the APACHE II score, and mortality in candidemic patients [14, 23–25, 40]. In our study, we used the SAPS II score but despite being higher in non-survivors (52 vs 47, p = 0.095), we could not prove it was an independent risk factor for mortality. A possible explanation is the fact that this score was calculated on admission and may not reflect the severity of the patients at the time of BSI diagnosis.

The need for mechanical ventilation as an independent risk factor for mortality has also been reported by several authors. In a prospective, multicenter, observational French study [5], the use of mechanical ventilation increased the odds of dying in the ICU 2.54 times (95 % CI 1.33–4.82, p = 0.0045). A similar result was reported in another large retrospective study (n = 987 patients with candidemia) [41] that showed an independent association between mechanical ventilation and 30-day mortality (OR 2.61, 95 % CI 1.81–3.78, p <0.001). An even higher impact was observed in a study with 173 ICU-acquired episodes of candidemia, in which the need of mechanical ventilation was associated with a four times increased risk of death (95 % CI 1.93–8.41, p <0.001) [19]. Almirante et al. also reported that intubation (OR 7.5, 95 % CI 2.6–21.1) was associated with higher odds of 30-day mortality in a cohort of 345 patients with candidemia, of whom 33 % were in the ICU at diagnosis [42].

In our cohort, medical patients had a lower probability of survival. Interestingly, the same result was reported by Charles et al. [37] a few years ago in a small study of 51 ICU patients with candidemia, in which medical patients had a higher mortality rate compared to surgical patients (85 % vs 45.2 %) and prior surgery was an independent factor associated with survival (HR 0.25, 95 % CI 0.09–0.67, p <0.05). Other authors [19] observed that the chances of dying with candidemia are 6.97 times higher in patients without multi-trauma (95 % CI 1.64–29.67, p = 0.009).

Although our study is multicenter, prospective and includes a significant number of patients, it has some limitations. It is not representative of the populations of healthcare systems in the 24 participating countries, and in some countries the number of patients included was very small. Each participating ICU performed investigations and laboratory testing according to their local protocols. The data were entered into the electronic case report...
form by investigators at each center, which may have increased the risk of inconsistency. Finally, some important variables with potential impact on the outcome were not considered, namely the antifungal agent used, its appropriateness and the timing of central venous catheter removal.

Conclusion
In summary, this multicenter international study showed that fungi are an important cause of HA-BSI in patients admitted to the ICU. No significant differences were observed between patients with bacteremia and fungemia, except for the presence of septic shock and renal dysfunction on ICU admission and renal failure at diagnosis, which were more frequent in HAF. Fungemia is significantly associated with 28-day all-cause mortality. We were not able to detect an independent association between timing of antifungal therapy and outcome, and only liver failure, need for mechanical ventilation and ICU admission for medical reasons were independent risk factors associated with mortality.

Key messages
- A fungus is likely to be the cause of a hospital-acquired BSI in patients with septic shock and renal dysfunction on ICU admission or with renal failure at BSI diagnosis
- In patients with hospital-acquired fungemia, the presence of liver failure, the need for mechanical ventilation and ICU admission for medical reasons significantly increase the odds of dying at day 28

Additional file
Additional file 1: Table S1. Baseline characteristics of patients with fungemia. Table S2 Characteristics of fungemia episodes at diagnosis. (DOCX 19 kb)

Abbreviations
APACHE: Acute Physiology and Chronic Health Evaluation; BSI: bloodstream infection(s); HA-BSI: hospital-acquired bloodstream infection(s); HAF: hospital-acquired fungemia; HR: hazard ratio; ICU: Intensive Care Unit; IQR: interquartile range; OR: odds ratio; SAPS: Simplified Acute Physiology Score; SOFA: Sepsis-related Organ Failure Assessment.

Competing interests
JAP has received a speaker or advisory board honorarium from Astellas, Gilead, Merck-Sharp-Dohme, Novartis and Pfizer. JMP has received a speaker honorarium from Gilead, Merck-Sharp-Dohme and Pfizer. GD has received a speaker and advisory board honorarium from Bayer, Pfizer, Astellas and Cubist and research grants from EC "Magic Bullet". MA has received research grants from Orion, Merck-Sharp-Dohme, Cubist, Pfizer and Pfizer and research grants from Astellas, Merck-Sharp-Dohme, Pfizer and Pfizer and research grants from Astellas, Merck-Sharp-Dohme, Pfizer and Pfizer, and research grants from Astellas, Merck-Sharp-Dohme, Pfizer and Pfizer. AT, FBC and DK have no conflicts of interest.

Authors’ contributions
JAP and JMP conducted the primary analysis and drafted the manuscript. AT contributed to the study design, data collection and analysis. JFT participated in the study conception and design, collection of data and analysis. JR and GD contributed to the study design and data collection. All authors have made substantial contribution to the revising and final approval of the version to be published.

Acknowledgements
The EUROBACT study was designed by the infection section of the ESICM. The study was endorsed by the European Critical Care Research Network (ECCRN) in May 2009 and received the Clinical Research Award with a research grant of €20,000 from the ECCRN in November 2011. The manuscript was written on behalf of the EUROBACT study group listed below. Grants were obtained from Université Grenoble 1 and European Society of Intensive Care Medicine.

Members of the EUROBACT study group Steering Committee: Alexis Tabah, Despoina Koulenti, Stijn Blot, Jean-Ralph Zahar, Maité Garroute-Orgeas, and Jean-François Timsit.
EUROBACT Scientific Committee: Jean Carlet, Christian Brun-Buisson, Georges Dimopoulos, Claude Martin, and Jordi Rello.

Statistics and methodology: Jean-François Timsit, Alexis Tabah, and Kevin Laupland.

Biostatistician: Aurélien Vesin.

Study monitoring: Alexis Tabah and Sylvain Anselme.

Country coordinators: Australia: Jeffrey Lipman; Austria: Andreas Valentini; Belgium: Johan Decruyenaere; Brazil: Frederico Bruzzi de Carvalho; Canada: Kevin Laupland; China: Xiaochun Ma; Croatia: Ivan Gornik; France: Benoit Misset; Germany: Wolfgang A. Krueger; Greece: Despoina Koulenti; Hungary: Akos Csomos; Italy: Massimo Antonelli; Japan: Toshiki Mizobe; Morocco: Said Motaouakkil; The Netherlands: Marc J.M. Bonten; Poland: Adam Mikułtacki; Portugal: José-Artur Paiva; Republic of Serbia: Uros Batranovic; Romania: Daniela Filipsescu; Spain: Jordi Valles & Ricard Ferrer; Switzerland: Philippe Eggimann; Tunisia: Feki Abroug; Turkey: Nahit Çakar; United Arab Emirates: Hussain Al Rahma.

ICU investigators, listed by ICU (by country):
Jeffrey Lipman (Prof., MD) - Department of Intensive Care Medicine, Royal Brisbane & Women’s Hospital, Brisbane, Australia; Anne Leditschke (MD) and Helen Rodgers (RN) - Canberra Hospital Intensive Care Unit, Canberra Hospital, Canberra; David Milliss (ASC Prof) and Thomas Gottlieb (ASC Prof) - Intensive Care Services, Concord Hospital, NSW, Australia; Stuart Baker (MD) and Brigit Roberts (RN) - ICU, Sir Charles Gardiner Hospital, Perth, Australia; Peter Krafft (MD) and Silvia Berneiter (MD) - Intensiv 1b, Hospital Rudolfstiftung, Vienna, Austria; Pieter Depuydt (MD) - Intensieve Zorg, Universitair Ziekenhuis Gent, Ghent, Belgium; Philippe Jammere (MD) - ICU A3 And C3, Jessa Hospital, Campus Virga Jesse, Hasselt, Belgium; Hervé Lebbirck (MD) - IU Az Sint-Augustinus; Veurne, Veurne, Belgium; Frederico Bruzzi de Carvalho (MD) and Juliana Pereira (MD) - Centro De Terapia Intensiva, Hospital Mater Dei, Belo Horizonte, Brazil; Aline Carrilheiro Yehia (MD), Felipe Carrilha Machado (MD), and Ana Luiza Horta de Sa Cameiro (MD) - Cti Hospital Julia Kubitschek, Belo Kubitschek, Belo Horizonte, Brazil; Antonio Fagundes Jr. (MD) - Unidade de Terapia Intensiva, Hospital do Coração do Brasil, Brasília - DF, Brazil; Fernando Rodríguez (MD) - Cti, Hospital de Clínicas Niterói, Niterói, Brazil; Marco Soares (MD, PhD) and Jorge Salluh (MD, PhD) - Cti, Instituto Nacional de Cancer, Rio De Janeiro, Brazil; Renata Beranger (MD) - ICU, São Lucas Hospital, Rio de Janeiro, Brazil; Marcelo Lugarinho (MD) - Cti Do Hospital De Clínicas Mario Lioni, Hospital De Clínicas Mario Lioni, Rio de Janeiro, Brazil; Alexandre Carvalho (MD) and Livia, Reri (RN) - Uti 1-2-3, Udi Hospital, São Luís - MA, Brazil; Lyu, Cynya de Lima (MD) - Uti Clinica, Hospital Santa Izabel, Salvador, Brazil; Claudio Piras (Prof., MD, PhD) - CPC, Vitoria Apart Hospital, Vitoria, Brazil; Eliana Caser (Prof) and Jansen Falcão (MD) - Uti Geril Adulto, Centro Integrado De Atención A Saúde - Cis Unimed Vitoria, Vitória - ES, Brazil; Kevin B Laupland (MD) - ICU, Peter Lougheed Centre, Calgary, Canada; Kevin B. Laupland (MD) - ICU, Foothills Medical Centre, Calgary, Canada; Kevin B. Laupland (MD) - CWIC, Foothills Medical Centre, Calgary, Canada; Kevin B. Laupland (MD) - ICU, Rockyview General Hospital, Calgary, Canada; Zhidan Zhang (MD) and Xiaochun Ma (MD) - Department Of Critical Care Medicine, The First Affiliated Hospital Of China Medical University, Shenyang, China; Xiao Yan Wang (Prof) - Ju Zhi Zhang (Prof) - Department Of Intensive Care Medicine, The First Affiliated Hospital Of Dalian Medical University, Dalian, China; Ke-Jian Qian (Prof) - Liang Xia (MD) - Intensive Care Unit, The First Affiliated Hospital Of Nan Changhai.
Author details

1 Grupo de Infección e Sepsis; Emergency and Intensive Care Department, Centro Hospitalario S. João, Porto, EPE, Faculty of Medicine, University of Porto, Porto, Portugal. 2Université Grenoble 1, U 823, Albert Bonniot Institute; Team 11: University Hospital, Kirikkale, Turkey; Ahmet Cagatay Oral (Prof., MD) - Ugur Goktas (ASC Prof.) - Medical Interventional Care Unit, Yuzuncu Yil University Medical Faculty, Van, Turkey; Arslan El Houfi (MD, MS, FRCP) - Micu-Sicu, Dubai Hospital, Dubai, United Arab Emirates.

References

1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302:2523–9.
2. Beck-Sague C, Jants WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis. 1993;167:1247–51.
3. Wispelwiy H, Bischoff T, Tallett SJ, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a retrospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–17.
4. Basetti M, Right E, Costa A, Fasce R, Molinari MP, Rosso R, et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006;6:21.
5. Leroy Q, Gagneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. 2009;37:1612–8.
6. Kett DH, Azoulay E, Echeverrim PM, Vincent JL. Extravascular Infection in ICU Study (ERIC II) Group of Investigators. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011;39:665–70.
7. Tabah A, Koutkia L, Laupland K, Misset B, Valles J, Bruzzi D, et al. Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT-INT Study. Intensive Care Med. 2011;37:1247–51.
8. Arnold HM, Micek ST, Shorr AF, Zilberberg MD, Labelle AJ, Kothari S, et al. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy. 2010;30:361–8.
9. Bassetti M, Trecarchi EM, Righi E, Sanguinetti M, Bisio F, Posteraro B, et al. Incidence, risk factors, and predictors of outcome of candidemia: survey in 2 Italian university hospitals. Diagn Microbiol Infect Dis. 2007;58:325–31.
10. Bouza E, Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents. 2008;32:587–91.
11. Picazo JJ, Gonzalez-Romo F, Cardell FJ. Candidemia in the critically ill patient. Int J Antimicrob Agents. 2008;32:583–5.
12. Falagas ME, Apostolou KE, Papas VD. Attributable mortality of candidemia: A systematic review of matched cohort and case control studies. Eur J Clin Microbiol Infect Dis. 2006;25:419–25.
13. Gudbjorgsson O, Gillespie S, Lee K. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37:1172–7.
14. Nolla-Salas J, Sitges-Serra A, Leon-Gil C, Martinez-Gonzalez J, Leon-Regidor MA, Ibanez-Lucia P, et al. Candidemia in nonneutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med. 1997;23:23–30.
15. Voss A, Le Noble JL, Verdun Lunel FM, Foudraune NA, Meis JF. Candidemia in intensive care unit patients: risk factors for mortality. Infection. 1997;25:8–11.
16. Lundberg IS, Piel TM, Wiblin T, Costigan MG, Dawson J, Nettleton MD, et al. Septic shock: an analysis of outcomes for patients with onset on hospital wards versus intensive care units. Crit Care Med. 1998;26:1020–4.
17. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med. 1988;148:2642–5.
18. Bassetti M, Righi E, Ansaldi F, Merelli M, Cecilia T, De Pascale G, et al. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med. 2014;40:839–45.
19. Marron D, Playford EG, Chen S, Slavin M, Nguyen Q, Ellis D, et al. Determinants of mortality in non-neutropenic ICU patients with candidemia. Critical Care. 2009;13:R115.
20. Le Gall JR, Lemeshev S, Sauhin F. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957–63.
21. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707–10.
22. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13:818–29.
23. Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med. 2008;36:2967–72.
24. Holley A, Dulhunty J, Blot S, Lipman J, Lobo S, Dancer C, et al. Temporal trends, risk factors and outcomes in albicans & non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. Int J Antimicrob Agents. 2009;33:554.e1–554.e7.
25. González de Molina FJ, León C, Ruiz-Santana S, Saevedra P, the CAVA I Study Group. Assessment of candidemia-attributable mortality in critically ill patients using propensity score matching analysis. Crit Care. 2012;16:R105.
26. Colombo AL, Guimaraes T, Sukienik T, Pasqualotto AC, Andreotti R, Queiroz-Telles F, et al. Prognostic factors and historical trends in the epidemiology of candidemia in critically ill patients: an analysis of five multicenter studies sequentially conducted over a 9-year period. Intensive Care Med. 2014;40:1489–98.
27. Blot S, Vandewoude KH, Hoste EA, Colardyn FA. Effects of Nosocomial Candidemia on Outcomes of Critically Ill Patients. Am J Med. 2002;113:480–5.
28. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–96.
29. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640–5.
30. Garey KW, Rege M, Pai MP, Mingo DE, Sudha KJ, Turpin RS, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25–31.
31. Patel GP, Simon D, Scheetz M, Crank CW, Lodise T, Patel N. The effect of time to antifungal therapy on mortality in Candidemia associated septic shock. Am J THER. 2009;16:508–11.
32. Parkins MD, Sabuda DM, Elayed S, Laupland KB. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J Antimicrob Chemother. 2007;60:513–8.
33. Klevay MJ, Ernst EJ, Hollanbaugh JL, Miller JG, Pfaller MA, Diekema DJ. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis. 2008;60:273–7.
34. Arendrup MC, Sulfim S, Holm A, Nielsen L, Nielsen SD, Knudsen JD, et al. Diagnostic issues, clinical characteristics and outcomes for patients with fungemia. J Clin Microbiol. 2011;49:3300–8.
35. Kudze-Forson M, Eschenauer GA, Kubin CJ, Della-Latta P, Lam SW. The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection. Med Mycol. 2010;48:436–9.
36. Grim SA, Berger K, Teng C, Gupta S, Layden JE, Janda WM, et al. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother. 2012;67:707–14.
37. Charles PE, Doise JM, Quenot JP, Aube H, Dalle F, Chavanet P, et al. Candidemia in critically ill patients: difference of outcome between medical and surgical patients. Intensive Care Med. 2003;29:2162–9.
38. Puig-Assensio M, Padilla B, Garnacho-Montero J, Zaragoza O, Aguado JM, Zaragoza R, et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect. 2015;21:491–500.
39. Pratikaki M, Platsouka E, Sotropoulou C, Douka E, Paramythiotou E, Kaltas P, et al. Epidemiology, risk factors for and outcome of candidaemia among non-neutropenic patients in a Greek intensive care unit. Mycoses. 2011;54:154–61.
40. Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, Ruiz-Pérez de Paínó M, Hernández-Caballeiro C, Lepe-Jiménez JÁ. Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections. J Antimicrob Chemother. 2013;68:206–13.
41. Guimarães T, Nucci M, Mendonça JS, Martinez R, Brito LR, Silva N, et al. Epidemiology and predictors of a poor outcome in elderly patients with candidemia. Intern J Infect Dis. 2012;16:e442–7.
42. Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planas AM, Almela M, et al. Epidemiology and predictors of mortality in cases of Candida Bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol. 2005;43:1829–35.